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Variations associated with the DNA analysis of multiple fine needle
aspirates obtained from breast cancer patients
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Summary The present study was carried out to determine the variation in DNA content between multiple
fine needle aspirates (FNA) of the same tumour from patients with breast cancer. Analysis of different
aliquots of the same FNA showed good reproducibility in terms of cell cycle distribution and DNA index.
Duplicate FNAs taken from different sites in nine of 11 excised tumours showed similar reproducibility.
However, two of the aneuploid tumours displayed substantial variations in the distribution of cell populations
between the duplicate samples. Sequential FNAs with no intervening therapy were obtained from the same
tumour in 17 patients; one at the time of diagnosis and the other at biopsy 1-3 weeks later. Only five cases
showed no variation between the sequential FNAs; the remaining 12 displayed different DNA profiles. A
further 13 patients were studied before and during systemic therapy. While there was no variation between
sequential FNAs in four patients, marked differences in the DNA profile were observed in the remaining nine
patients undergoing treatment, the changes not necessarily being associated with clinical response to therapy.
It is concluded that the monitoring of cellular changes by DNA analysis of sequential FNAs may be complex
and subject to problems associated with heterogeneity.
Flow cytometric DNA analysis can provide useful
information on the cellular characteristics of breast tumours
(Auer et al., 1980; Baildam et al., 1987; Cornelisse et al.,
1987; Dowle et al., 1987; Kallioniemi et al., 1987a, b;
Owainati et al., 1987). Recently, we demonstrated that fine
needle aspiration of most breast cancers can provide
sufficient cellular material for meaningful analysis of DNA
profiles using flow cytometry (Levack et al., 1987). This use
of flow cytometry in the analysis of cellular material from
FNAs has potentially wide applications. For example, it may
be possible to monitor the effects of treatment by analysing
cellular characteristics of sequential tumour FNAs.
In this respect it is important to show that analysis of
FNAs provides reproducible results. The aim of the present
paper was to assess variation in DNA profiles by studying
multiple fine needle aspirates taken simultaneously and
sequentially from breast tumours.
Patients and methods
Patients
Tumour fine needle aspirates (FNAs) were obtained from
patients attending the Professorial Breast Clinics of the
University Department of Surgery, Edinburgh. All tumours
were shown histologically to be breast cancers and malignant
cells were cytologically confirmed to be present in all
aspirates.
Aspirates
The method of aspiration was that described by Zajicek
(1965) and used a 23 gauge needle attached to a 10 ml
syringe. After removing an aliquot for cytological
confirmation of malignancy (Dixon et al., 1984), the
remainder of the aspirate was expelled into 200dp of citrate
buffer and stored at -40°C until analysis (Vindel0v et al.,
1983a, b).
Flow cytometric DNA analysis
Flow cytometric DNA analysis was carried out as described
previously (Levack et al., 1987), except that trout
erythrocytes were omitted since flow cytometric analysis of
standard preparations frequently produced peaks with DI
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values falling within the 'S' phase fraction of diploid tumour
cells.
Briefly, frozen cell suspensions were thawed in a water
bath at 370C and chicken erythrocytes added as an internal
standard (Vindel0v et al., 1983c). The cell suspension was
then trypsinised for 10min at room temperature. After a
further 10min incubation with trypsin inhibitor and RNAse,
the cells were stained with propidium iodide and spermine
tetrachloride at 0°C. Samples were passed through a gauge
23 needle prior to analysis.
DNA content was analysed after counting 10,000 sample
nuclei using an EPICS C flow cytometer (Coulter Electronics
Ltd., Hileah, Florida). Full peak coefficients of variation of
GO/I peaks, as calculated using the Coulter statistics
software, had a range of 2.09-7.84 (mean 4.02).
Reproducibility within a single sample
Aliquots of individual FNAs were analysed on two separate
occasions, specimens being stored at -40°C during the
intervening period.
Reproducibility between multiple samples taken simultaneously
Two samples were prepared from a single excised specimen
in which FNAs were taken from two separate areas at a
distance apart. Aspirates were processed separately but in
the same batch.
Reproducibility between multiple samples taken sequentially
Two separate series of sequential aspirates were studied,
either with or without intervening systemic treatment.
Investigations of sequential aspirates from patients not
receiving systemic therapy involved the comparison of FNAs
taken for diagnostic purposes with those from excised
tumour taken 1-3 weeks later. Sequential aspirates obtained
from women undergoing systemic treatment were obtained
from patients with large but operable breast tumours
(Forrest et al., 1986).
In all comparisons, samples were regarded as being
substantially different if (a) the DNA index (DI) varied by
more than 5%, (b) the percentage of diploid cells in any
phase of the cycle varied by more than 10%, or (c) the
absolute number of aneuploid cells varied by more than
10%.
Results
Using the chicken red blood cells as an internal DNA
standard, the mean DI of diploid GO/I cells was found to be
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0.997+0.039. The degree of concordance between replicate
samples from the various studies is summarised in Table I.
Of 17 duplicate FNA aliquots prepared and analysed on
two separate occasions, all eight diploid and eight of nine
aneuploid tumours showed similar DNA profiles. However,
in one tumour the percentage of aneuploid cells decreased
from 75% at first estimation to 50% on reassay.
Duplicate FNAs were obtained from different sites in 11
specimens of excised tissue. All six diploid cases gave
duplicate results which were similar both for DNA index and
cell cycle distribution. Of the remaining five aneuploid
tumours, duplicates in three produced concordant results but
two cases showed differences in the relative distribution of
cell populations between replicates. In the first tumour, one
replicate FNA had 87% diploid and 13% aneuploid cells
while the other had 71% and 29% respectively. In the
second tumour the difference related to the relative
proportions of two aneuploid sub-populations, which
amounted to 8% and 38% in one replicate and 29% and
24% in the other.
In 17 patients it was possible to compare aspirates taken
for diagnosis with those from excised specimens of the
tumour taken 1-3 weeks later. In only five cases (one diploid
and four aneuploid) did the FNAs produce similar profiles
after flow cytometric analysis. In contrast, two diploid
tumours showed marked changes in cell cycle distribution,
an increase in the 'S' phase being evident in the FNA from
one excised tissue, a decrease in the other. Substantial
differences were also evident in a further 10 aneuploid
tumours (examples are shown in Figure 1); in two cases an
additional aneuploid cell population appeared in the biopsy
specimen (Figure 1a); in two cases the proportion of
aneuploid to diploid cells increased; in two cases the
proportion of aneuploid to diploid cells decreased (Figure
lb); in one case there was a substantial redistribution of cell
numbers within two aneuploid subpopulations (Figure lc)
and in three cases the DI of an aneuploid cell line increased
markedly (Figure ld).
FNAs were obtained before and during systemic therapy
in 13 patients. Four tumours showed no evidence of
variation between samples (three diploid and one aneuploid)
before and after treatment. In contrast, marked differences
in the DNA profile were observed in the remaining patients
undergoing treatment, examples being illustrated in Figure 2.
In one tumour where initial analysis showed only diploid
cells, an aneuploid population appeared after treatment
(Figure 2a). The remaining tumours were consistently
aneuploid; in one an aneuploid cell line disappeared (Figure
2b), in one the proportion of aneuploid cells decreased with
treatment while in four it increased (Figure 2c). The
remaining two tumours showed an increase in the DNA
index with therapy. These variations were not necessarily
associated with changes in tumour volume as assessed by
clinical and mammographic measurements.
Table I Degree of concordance found in duplicate
FNAs assayed for relative DNA content
Diploid Aneuploid Total
I 8/8 (100%) 8/9 (89%) 16/17 (94%)
II 6/6 (100%) 3/5 (60%) 9/11 (82%)
III 1/3 (33%) 4/14 (29%) 5/17 (29%)
IV 3/3 (100%) 1/10 (10%) 4/13 (31%)
Comparisons have been made between (I) aliquots
of the same FNA assayed on two separate occasions,
(II) duplicate FNAs obtained from excised biopsy
material, (III) an FNA at diagnosis with that derived
from biopsy material excised 1-3 weeks later, and (IV)
an FNA taken at diagnosis with that from the same
tumour after 1-13 weeks of systemic therapy.
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Figure 1 Diagrammatic representations of DNA histograms
obtained from patients in whom diagnostic FNAs (i) have been
compared with biopsy material excised subsequently (ii). In all
cases peaks 1 and 2 represent nucleated chicken red blood cells
and diploid nuclei in the GO/I phase of the cycle respectively. (a)
At diagnosis there was a single diploid cell line (peak 2) whereas
biopsy material reveals a previously undetectable aneuploid cell
line (peak 4). Peak 3 presumably represents the fraction of cells
in the G2/M phases of peak 2. (b) At diagnosis there is a large
population of aneuploid cells with a DI of 1.94 (peak 3). This is
no longer detectable at biopsy. (c) This tumour showed a
redistribution of cell numbers between sequential FNAs. At
diagnosis the two aneuploid peaks (3 and 4) contained 8% and
81% of the cells respectively whereas at biopsy the same two
peaks had 75% and 5% of the total cells respectively. (d) An
example in which the DNA index of an aneuploid cell line (peak
3) has increased from 1.76 at diagnosis to 1.96 at excision.
Discussion
There is good evidence from both static and flow cytometric
DNA analysis of paraffin embedded material or freshly
excised tissue that patients with DNA diploid tumours are
likely to have a better prognosis than their DNA aneuploid
counterparts (Auer et al., 1980; Baildam et al., 1987;
Kallioniemi et al., 1987a, b). We have recently reported that
sufficient cellular material for meaningful flow cytometric
DNA analysis can be obtained from the majority of routine
diagnostic FNAs (Levack et al., 1987). This study attempts
to validate the reproducibility of such FNAs in the light of
the heterogenous nature of certain breast tumours.
As previously reported by Vindelov et al. (1983a), storage
of tumour FNAs in citrate buffer for varying times before
assay did not markedly affect the results. Thus, in 16/17
cases the DNA content of replicate aliquots of individual
FNAs showed no substantial variation in the DNA index
(DI), the percentage of cells in any phase of the cycle or the
ratio of aneuploid to diploid cells even when assayed on
separate occasions. No reason was found for the discrepancy
observed in the remaining DNA aneuploid sample. Storage
of FNAs before analysis was therefore regarded as
satisfactory and unlikely to cause variations in the cellular
DNA profiles obtained from FNAs. The analysis of fresh
material is therefore unnecessary.
Comparison of FNAs obtained simultaneously at two
different sites from excised tumour showed little variation in
all six diploid and three of five aneuploid tumours. However,
the remaining two aneuploid tumours did display major
discrepancies in DNA profile. This suggests that even when
the tumour material has been excised, heterogeneity may still
cause problems in assessing cellular characteristics in a
minority of cancers.690 P. MULLEN & W.R. MILLER
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Figure 2 Diagrammatic representations of DNA histograms
obtained from patients undergoing systemic therapy. FNAs were
carried out before (i) and during (ii) treatment. (a) shows results
from a patient before and after 11 weeks treatment with an
LHRH agonist. The FNA from the treated tumour shows the
appearance of a large population of DNA aneuploid cells with a
DI of 1.77 (peak 3). (b) shows results from a patient undergoing
treatment with mitoxantrone. After 4 weeks the aneuploid
component has fallen from 82% to 26%. (c) shows results from
a patient in whom the relative proportion of aneuploid to diploid
cells has increased from 32% to 85% (peak 3) after 13 weeks
treatment with an LHRH agonist.
The likelihood of discordance between FNAs from the
same tumour became more apparent when comparing biopsy
specimens with their respective diagnostic FNA. Despite the
time interval between aspirations being only 1-3 weeks and
no therapy having been administered, only 1/3 diploid (33%)
and 4/14 aneuploid (29%) tumours showed similar DNA
profiles. Three tumours showed an increase in the DI of
aneuploid cells. This is particularly interesting since it implies
that either a single cell line has undergone clonal evolution
resulting in a net gain of DNA per cell, or genetically
distinct populations of tumour cells have been sampled. The
latter possibility implies that FNAs are not necessarily
representative of the tumour mass.
Since the majority of tumours show differences between
sequential FNAs in the absence of intervening treatment, it
is not surprising that similar discordance was observed
between sequential aspirates taken from patients undergoing
systemic therapy. Although hormone therapy has been
associated with marked changes in the DNA content of
breast tumours (Baildam et al., 1987), it is not possible in
this study to attribute the variation observed with systemic
therapy to treatment response. This is not only because
similar changes may be observed in the absence of therapy,
but also because, in patients receiving treatment, the
differences between successive FNAs are not necessarily
related to response. It is therefore clear that the
interpretation of data from sequential FNAs will be
complicated by problems associated with (a) the proportion
of tumour to non-tumour cells in the aspirate, and (b)
heterogenity, which appears to be present in a high
proportion of breast cancers (Kallioniemi, 1988). These
problems are not specific to DNA analysis and other
biochemical parameters such as oestrogen receptor status
and cAMP binding display similar variations within tumours
(Senbanjo et al., 1986).
In conclusion, major discordances between replicate FNAs
have been demonstrated in the minority of tumours sampled
concurrently and the majority of tumours aspirated
sequentially. These differences, which are probably caused by
tumour heterogeneity, suggest that monitoring cellular
changes by fine needle aspiration of breast tumours may not
be feasible and will be complicated by sampling errors.
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